Price T Rowe Associates Inc Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $24 Million - $25.2 Million	-165,323 Reduced 31.7%	356,257 $53.9 Million
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $482,960 - $848,055	5,809 Added 1.13%	521,580 $76 Million
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $5.48 Million - $7.12 Million	49,794 Added 10.69%	515,771 $61.2 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $4.16 Million - $6.2 Million	41,760 Added 9.84%	465,977 $64.2 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $5.29 Million - $7.43 Million	53,488 Added 14.43%	424,217 $58.9 Million
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $14.2 Million - $22.7 Million	216,182 Added 139.88%	370,729 $36 Million
Q1 2021 May 17, 2021	SELL	$64.07 - $91.75 $10,827 - $15,505	-169 Reduced 0.11%	154,547 $10.6 Million
Q4 2020 Feb 16, 2021	BUY	$65.07 - $98.24 $10.1 Million - $15.2 Million	154,716 New	154,716 $13.3 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.